Search Results
Mar 17, 2026, 14:50 ET RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study." The press release also disclosed that "[t]he FDA also placed a clinical hold on RGX-121, for
More news about: Faruqi & Faruqi, LLP
Mar 17, 2026, 10:13 ET NIH-Funded Randomized Clinical Trial Evaluating Weekly BRIXADI® for Opioid Use Disorder in Pregnancy and 12-months Postpartum Published in JAMA Internal Medicine
emergency medical help, even if an agent is administered. Concomitant Use of Benzodiazepines or other CNS Depressants: Concomitant use of buprenorphine and benzodiazepines or other CNS depressants (e.g., alcohol, non-benzodiazepine sedative/hypnotics, anxiolytics, tranquilizers, muscle relaxants,
More news about: Braeburn
Mar 17, 2026, 09:00 ET Apertura Gene Therapy and Viralgen Announce Strategic Collaboration to Manufacture TfR1 CapX, a Next-Generation Capsid for Gene Therapies Designed to Treat Central Nervous System Diseases
that is designed to bind to human TfR1, cross the blood-brain barrier, and broadly transduce tissues in the CNS while administered at low doses. TfR1 CapX has demonstrated selectivity to the CNS compared to other tissues, with robust transduction of neurons and astrocytes across different brain regions,
More news about: Viralgen
Mar 17, 2026, 09:00 ET Apertura Gene Therapy and Viralgen Announce Strategic Collaboration to Manufacture TfR1 CapX, a Next-Generation Capsid for Gene Therapies Designed to Treat Central Nervous System Diseases
that is designed to bind to human TfR1, cross the blood-brain barrier, and broadly transduce tissues in the CNS while administered at low doses. TfR1 CapX has demonstrated selectivity to the CNS compared to other tissues, with robust transduction of neurons and astrocytes across different brain regions,
More news about: Viralgen
Mar 17, 2026, 09:00 ET RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit -- The Gross Law Firm
press release announcing that the FDA placed a clinical hold on its investigational gene therapy RGX-111. Defendants announced that an intraventricular CNS tumor was found in a participant treated in its RGX-111 Phase I/II study. Following this news, the price of REGENXBIO's common stock declined from a
More news about: The Gross Law Firm
Mar 16, 2026, 23:00 ET Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference
to kidney, more targeted drug candidates are under preclinical development to further extend the therapeutic reach to cardiac, adipose, muscle, and CNS disorders. Ribo will continue to advance ex-liver products in order to bring innovative siRNA therapeutics to patients worldwide.Logo -
More news about: Suzhou Ribo Life Science Co., Ltd.
Mar 16, 2026, 23:00 ET Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference
to kidney, more targeted drug candidates are under preclinical development to further extend the therapeutic reach to cardiac, adipose, muscle, and CNS disorders. Ribo will continue to advance ex-liver products in order to bring innovative siRNA therapeutics to patients worldwide.
More news about: Suzhou Ribo Life Science Co., Ltd.
Mar 12, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX
therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study." The press release also disclosed that "[t]he FDA also placed a clinical hold on RGX-121, for
More news about: Pomerantz LLP
Mar 12, 2026, 09:00 ET STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST
made a series of statements emphasizing that RGX-111 was "well-tolerated" with "no drug-related serious adverse events" and highlighting "encouraging CNS biomarker activity." These statements spanned multiple disclosure events:February 9, 2022: Announced "no drug-related serious
More news about: SueWallSt.com
Mar 12, 2026, 05:19 ET 이뮤노포지, 2026 Bio Europe Spring에서 전략적 파트너링 진행
계획이다.LMT15 Platform은 Leptin receptor-Mediated Transcytosis를 기반으로 ELP에 융합하여 BBB 투과와 장기 지속이라는 약물 개발의 두 가지 모달리티를 하나의 구조로 가능하게 하는 차별화된 플랫폼이며 이뮤노포지는 현재 특허를 출원하고 CNS 타깃 신약들을 본격적으로 개발하고 있다.이뮤노포지 관계자는 "Bio Europe Spring 2026 참석을 통하여 현재 임상 2상 진행 중인 PF1801과 FDA로부터 임상2상 IND 승인을 받은 PF1804에 대하여 논의 중인 해외 회사들과의 후속 논의를
More news about: ImmunoForge Co., Ltd.
Mar 12, 2026, 04:58 ET ImmunoForge to Conduct Strategic Partnering at Bio-Europe Spring 2026
and a novel peptide enabling on Leptin receptor-Mediated Transcytosis. ImmunoForge has filed a patent application on this technology and is developing CNS-targeted new drugs for its own pipeline. ImmunoForge is also open to partnering relationships to enable broad application of this technology.Key
More news about: ImmunoForge Co., Ltd.
Mar 11, 2026, 09:36 ET RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study." The press release also disclosed that "[t]he FDA also placed a clinical hold on RGX-121, for
More news about: Faruqi & Faruqi, LLP
Mar 11, 2026, 09:12 ET Cohen & Steers Announces Plan to Convert the Cohen & Steers Future of Energy Fund to ETF
NEW YORK, March 11, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today announced plans to convert the Cohen & Steers Future of Energy Fund, a U.S. mutual fund designed to capitalize on opportunities across traditional
More news about: Cohen & Steers, Inc.
Mar 11, 2026, 09:00 ET STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP
made a series of statements emphasizing that RGX-111 was "well-tolerated" with "no drug-related serious adverse events" and highlighting "encouraging CNS biomarker activity." These statements spanned multiple disclosure events:February 9, 2022: Announced "no drug-related serious
More news about: Levi & Korsinsky, LLP
Mar 11, 2026, 09:00 ET Investors who lost money on REGENXBIO Inc.(RGNX) should contact Levi & Korsinsky about pending Class Action - RGNX
press release announcing that the FDA placed a clinical hold on its investigational gene therapy RGX-111. Defendants announced that an intraventricular CNS tumor was found in a participant treated in its RGX-111 Phase I/II study. Following this news, the price of REGENXBIO's common stock declined from a
More news about: Levi & Korsinsky, LLP
Mar 11, 2026, 04:00 ET ARTHEx Biotech Granted FDA Fast Track Designation for ATX-01 for the Treatment of Myotonic Dystrophy Type 1 (DM1)
I/IIa ArthemiR™ trial. Building on this foundation, ARTHEx is advancing a pipeline of therapies for additional areas of high unmet need across muscular, CNS and cardiac diseases.The Company headquarters are in Valencia, Spain. For more information on ArthemiR™, please visit
More news about: ARTHEx Biotech
Mar 10, 2026, 20:48 ET 貴州の山水の中で体感する東洋文化の魅力
https://www.prnewswire.com/jp/news-releases/-302710210.htmlSOURCE CNS
More news about: CNS
Mar 10, 2026, 16:01 ET Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the Stifel 2026 Virtual CNS Forum at 4:30 PM EST on March 17, 2026.
More news about: Neurocrine Biosciences, Inc.
Mar 10, 2026, 11:16 ET GenomOncology Announces Strategic Partnership with WeTrials to Accelerate Clinical Trial Enrollment for CNS Cancer Patients
medicine software company, today announced a strategic partnership with WeTrials, an AI-powered patient engagement and trial enablement platform, to help CNS cancer patients access and enroll in clinical trials faster. In addition to being made available to all customers at GenomOncology. The collaboration
More news about: GenomOncology
Mar 10, 2026, 09:00 ET TRIANGLE INSIGHTS GROUP BY VALERIS ANNOUNCES APPOINTMENT OF ERIN SOLANO TO PARTNER
strong analytical rigor to drive strategic decision-making across client domains. Triangle's expertise encompasses key therapeutic areas (oncology, CNS, and cell and gene therapy) and relevant industry disciplines (pricing and market access, new product planning, and commercial strategy). For more information,
More news about: Valeris
Mar 10, 2026, 09:00 ET Investors who lost money on REGENXBIO Inc.(RGNX) should contact The Gross Law Firm about pending Class Action - RGNX
press release announcing that the FDA placed a clinical hold on its investigational gene therapy RGX-111. Defendants announced that an intraventricular CNS tumor was found in a participant treated in its RGX-111 Phase I/II study. Following this news, the price of REGENXBIO's common stock declined from a
More news about: The Gross Law Firm
Mar 10, 2026, 05:59 ET EQT Foundation opens applications for science grants to overcome the blood-brain barrier and transform CNS drug delivery
localized or systemic CNS drug deliveryBiological and molecular BBB modulation: tight junction modulators, osmotic or chemical permeabilizers, and genetically or pharmacologically induced transient BBB opening with spatiotemporal control and strong safety rationale CNS-targeted gene therapies
More news about: EQT
Mar 10, 2026, 01:38 ET 구이저우의 산과 강 사이에서 동양 문화의 매력을 체험하다
https://www.prnewswire.com/kr/news-releases/uAD6CuC774uC800uC6B0uC758u002DuC0B0uACFCu002DuAC15u002DuC0ACuC774uC5D0uC11Cu002DuB3D9uC591u002DuBB38uD654uC758u002DuB9E4uB825uC744u002DuCCB4-302709004.htmlSOURCE CNS
More news about: CNS
Mar 09, 2026, 18:55 ET Myosin Therapeutics Invited to Present at Two South Florida Life Sciences Conferences
TherapeuticsMyosin Therapeutics is a biotechnology company based in Jupiter, Florida, developing first-in-class therapies for oncology and CNS disorders by targeting molecular nanomotor proteins. The company's lead program, MT-125, is being developed to address aggressive, treatment-refractory
More news about: Myosin Therapeutics Inc.
Mar 09, 2026, 16:20 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for February 2026
NEW YORK, March 9, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $98.4 billion as of February 28, 2026, an increase of $5.4 billion from assets under management
More news about: Cohen & Steers, Inc.